Your English writing platform
Discover LudwigExact(13)
Roughly 2.3 billion people -- more than a third of the world's population -- are at risk of infection, but since most of them live in the world's poorest countries and cannot buy expensive drugs, there has been no financial incentive for pharmaceutical companies to develop a malaria vaccine.
Kurtis said: "Many researchers are trying to find ways to develop a malaria vaccine by preventing the parasite from entering the red blood cell, and here we found a way to block it from leaving the cell once it has entered.
Few Africans can afford the expensive medicines that mitigate the effects of AIDS; and few drug companies will spend the quantities of money necessary to develop a malaria vaccine if most of the people likely to want it are too poor to buy it.
Currently, almost all efforts to develop a malaria vaccine have focused on P. falciparum.
This is one of the strategies that has been adopted in the quest to develop a malaria vaccine.
But 100% protection is the best result yet in the long and frustrating effort to develop a malaria vaccine.
Similar(47)
"It is a very exciting, encouraging result that establishes the feasibility of developing a malaria vaccine," he says.
Simultaneously, this finding provided a biological target for developing a malaria vaccine, the induction of cytophilic antibodies in young children.
RTS,S represents one approach to developing a malaria vaccine, based primarily on the induction of protective antibody responses.
This limitation will be alleviated by developing a "malaria-specific" pulsed laser with a wavelength ≈672 nm the focus of our ongoing effort because such lasers are not currently available.
Sanofi-aventis, a pharmaceutical firm based in Paris, has been working to develop a new malaria drug for children.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com